27 February 2020 **Sydney, Australia**

Noxopharm Corporate Presentation February 2020

Noxopharm (ASX: NOX) is pleased to provide shareholders and the market the attached corporate presentation, "Kalkine Invest Nest Presentation 27 February 2020".

This document will be used at the Kalkine Invest Nest 2020 Small Cap Investor Conference.

The presentation can be found at www.noxopharm.com

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc.

www.noxopharm.com

Investor & Corporate Enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media queries:
Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Graham Kelly, CEO and Chairman of Noxopharm has approved the release of this document to the market.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar

expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

February 2020

Noxopharm Limited

Veyonda®

Kalkine Invest-Nest Presentation – 27 Feb 2020

NOXOPHARM

ASX: NOX

DISCOVER DEVELOP DELIVER

Disclaimer

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

NOXOPHARM

Dr Gisela Mautner, *MD-PHD, MPH, MBA, FACPE*
Chief Medical Officer

- Prostate Cancer
- Veyonda®
- DARRT-Studies
- LuPIN-Study
- Clinical Program
- Veyonda® Market Potential

NOXOPHARM

Veyonda®



NOXOPHARM



1 in 5 men

develop prostate cancer before they turn 85

NOXOPHARM

In India

- The prevalence of prostate cancer in India was previously thought to be far lower compared to western countries
- BUT …
  - Increased migration from rural to urban areas
  - Changing life styles and diet
  - Increased awareness
  - Easier access to medical facilities
  - …
  - **More cases of prostate cancer are being picked up**

NOXOPHARM

Drug Development Process



NOXOPHARM

Veyonda® – Our Lead Drug



NOXOPHARM

Prostate Cancer and Treatment Options



NOXOPHARM

Veyonda® – Clinical Study DARRT-1

- 26 men enrolled with late-stage **prostate cancer**
- Metastatic castration-resistant prostate cancer (mCRPC)
- Progressive disease
- No remaining standard treatment options
- Eligible for palliative RT for symptomatic relief



Bone scan with metastatic disease

DARRT = Direct and Abscopal Response to Radiation Therapy; RT = Radiation Therapy

NOXOPHARM

DARRT-1: Efficacy Results - PSA

- Veyonda® in combination with radiation therapy appeared to be **safe and well-tolerated**[1]
- In the 16* patients who were evaluable at 6 months[1]

Over 50% drop in PSA in 5/16 patients

* 9 patients lost to follow-up, died or withdrew from study

PSA = prostate specific antigen

1. Noxopharm. Data on file.

NOXOPHARM

DARRT-1: Efficacy Results - Pain

- Veyonda® in combination with radiation therapy appeared to be **safe and well-tolerated**[1]
- In the 16* patients who were evaluable at 6 months[1]

Over 30% drop in pain levels In 10/16 patients

4 patients became completely pain-free

* 9 patients lost to follow-up, died or withdrew from study

1. Noxopharm. Data on file.

NOXOPHARM

DARRT-1: Efficacy Results – Tumour Response

- In the 15* patients who were evaluable at 6 months[1]



Tumors stopped growing in 9 patients



Tumors reduced in size in 1 patient

In summary, combination therapy of Veyonda® and radiotherapy showed major benefits to patients and underscores the Company's confidence in Veyonda® eventually becoming a standard drug in the management of prostate cancer

* 10 patients lost to follow-up, died, were not measurable or withdrew from study

1. Noxopharm. Data on file.

NOXOPHARM

Veyonda® Acts in a Unique Space



Irrespective of how many new drugs are coming to market, they will generally not affect the market space of Veyonda®

NOXOPHARM

DARRT-2 Trial: In Planning

- Building on the experience and data of DAART-1
- Phase 2 trial
- Multinational
- Min. 60 patients
- Same patient population as in DARRT-1
- Radiation therapy plus repeated cycles of Veyonda®
- Medical Advisory Boards established
- Protocol synopsis being drafted
- Anticipated regulatory submissions late-2020
- Study expected to commence in early-2021

✓ **We are developing the most efficient and impactful study possible!**

NOXOPHARM

Additional Opportunity in Prostate Cancer

External Radiation

- Standard-of-Care
- Widely used

DARRT

Internal Radiation

- Experimental
- Billion-dollar Acquisition by Novartis



LuPIN

NOXOPHARM

LuPIN Trial: Key Interim Results

❖ Comparison Veyonda® + ^{177}Lu-PSMA-617 vs ^{177}Lu-PSMA-617 alone

- Progression-free survival (PFS) is a measure of the time from the start of treatment until the disease progresses.



✓ Median PFS **quadrupled** through the addition of Veyonda® (8.4 months vs 2.0 months with ^{177}Lu-PSMA-617 alone)

NOXOPHARM

LuPIN Trial: Key Interim Results

❖ Veyonda® + ^{177}Lu-PSMA-617

- Overall Survival (OS) is a measure of the time from the start of treatment until death.

- ✓ Median OS was **17.1 months** – a remarkable result at this late stage of the disease
- ✓ The combination therapy was well tolerated, pointing to Veyonda® being safe to use in combination with intravenous radiotherapy

In summary, combination therapy of Veyonda® and ^{177}Lu-PSMA-617 showed major benefits to patients and underscores the Company's confidence in Veyonda® eventually becoming a standard drug in the management of prostate cancer

NOXOPHARM

Veyonda® - Pipeline



NOXOPHARM

Market Potential – Radiotherapy in Prostate Cancer



Potential Market Opportunities – Radiotherapy plus Veyonda®



NOXOPHARM

Mr Alex Hunter *MBA, BE, GradDipCorpSecFinLaw, GradDipAppFin*
Corporate Overview

Executive Summary

Company Details

NOXOPHARM

Veyonda®

Executive Summary

- ASX listed (NOX) since 2016
- Clinical stage drug development Company (mid-stage = substantially de-risked)
- Oncology focus. Proprietary drug Veyonda®
- Aiming at largest market sector in oncology – late-stage solid cancers where patients receiving just palliative care
- Successful drug = high probability of sharing in current US$100 billion + oncology drug market
- Focus initially on late-stage prostate cancer
- Last 2 deals in prostate cancer field were US$13 billion (Pfizer - 2016) and US$6 billion (Novartis - 2018)
- Experienced board and management team, strong technical & commercial experience

Noxopharm believes that its DARRT and LuPIN treatments will become standard of care for late-stage prostate cancer, offering patients and doctors two new treatment options

NOXOPHARM

Company Details

Noxopharm Limited *(Feb 2020)*	
Listed on Australian Securities Exchange (ASX:NOX)	
Shares on issue	152m
Share Price	A$0.205-A$0.365
Market Cap	A$31-55m
Cash	~A$3.5m

Board and Key Management	
Dr Graham Kelly. *PhD*	Chairman & CEO
Ian Dixon. *PhD, MBA*	Non-Executive Director
Peter Marks. *MBA, BEc, LLB*	Non-Executive Director
Dr Gisela Mautner. *MD-PHD, MPH, MBA*	Chief Medical Officer
Alex Hunter. *MBA, BE*	Chief Commercial Officer
Greg Ambra. *MS*	SVP North American Ops
Dr John Wilkinson. *PhD*	Chief Scientific Officer
Shawn Van Boheemen. *BBus MCom*	Chief Financial Officer



NOXOPHARM

For further information please visit

www.noxopharm.com

Veyonda®

NOXOPHARM

ASX: NOX

DISCOVER DEVELOP DELIVER